BioCentury
BioCentury
YouTubeLinkedInXRSS
ARTICLE | Distillery Therapeutics

A dual BRD4-EP300 inhibitor for pancreatic cancer

By Biocentury staff
March 4, 2022 7:49 PM UTC

DISEASE CATEGORY: Cancer

INDICATION: Pancreatic cancer...

BCIQ Company Profiles

University of Illinois at Chicago

BCIQ Target Profiles

Bromodomain containing 4 (BRD4)

E1A binding protein p300 (EP300) (p300)

KRAS proto-oncogene, GTPase (KRAS) (K-Ras)

MAP kinase (MAPK) (ERK)

BCIQ Company Profiles

University of Illinois at Chicago

BCIQ Target Profiles

Bromodomain containing 4 (BRD4)

E1A binding protein p300 (EP300) (p300)

KRAS proto-oncogene, GTPase (KRAS) (K-Ras)

MAP kinase (MAPK) (ERK)

About BioCentury

Privacy & Legal

Contact

About BioCentury

Company Overview
Management
Editorial & Research
Scientific Advisory Board

Privacy & Legal

User Agreement
Terms of Use
Privacy Policy
Use of Images & Market Data
Reprints & Permissions

Contact

Contact Us
Advertising & Sponsorship
Customer Resource Center
Career Opportunities
Forgot Password
YouTubeLinkedInXRSS
BioCentury
© 2026 BioCentury Inc. All Rights Reserved.
Copyright © 2026 BioCentury Inc. All Rights Reserved.
YouTubeLinkedInXRSS